Ensysce Biosciences Bought a Pain-Drug Startup and Lined Up as Much as $77.2 Million to Fund It Through 2028

Ensysce Biosciences, a clinical-stage biotechnology company, announced on August 6, 2026 that it had completed the acquisition of Cy Biopharma, a privately held developer of neuroplastogenic therapies — drugs designed to address the underlying neurobiology behind certain pain conditions rather than only managing symptoms — with an initial focus on Complex Regional Pain Syndrome (CRPS). Alongside the acquisition, the company disclosed $17.1 million in cash financing and a $21.5 million Series C preferred stock private placement, with a potential further $38.6 million follow-on tranche contingent on reaching a clinical trial milestone. The stated purpose of the combined funding is to carry Cy Biopharma's lead program, CY200, through 2028. The stock rose 25.1% in the fifteen minutes after the announcement.

For a small clinical-stage biotech, an acquisition paired with fresh financing is a package deal worth reading as one story, not two. The financing determines whether the acquired pipeline actually gets funded through the clinical milestones that would make it valuable; an acquisition without adequately-sized financing behind it is a much weaker signal than one with capital secured up front. Here, the disclosed financing — combining the immediate $17.1 million and $21.5 million pieces with a contingent $38.6 million tranche — is sized specifically against a stated runway target (through 2028), which is a more concrete commitment than a typical acquisition announcement offers on its own.

The private-placement structure, including preferred stock and a milestone-contingent follow-on tranche, is also a common financing shape for early-stage biotech: it lets new investors take a security with different terms than the common stock, and it ties the largest piece of new capital to the company actually hitting a defined clinical checkpoint rather than releasing it all up front.